NCT03138525View on ClinicalTrials.gov

Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

161

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions
Multiple SclerosisHealthy
Interventions
OTHER

Blood sampling (MS)

Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.

OTHER

Blood sampling (controls)

Blood samples will be collected once at enrollment.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT03138525 - Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis | Biotech Hunter | Biotech Hunter